Amarin Co. plc Lowered to Buy at Jefferies Group (AMRN)
Amarin Co. plc (NASDAQ:AMRN) was downgraded by research analysts at Jefferies Group to a “buy” rating in a report released on Thursday, American Banking & Market News reports. They currently have a $4.00 target price on the stock, down from their previous target price of $20.00. Jefferies Group’s price objective points to a potential upside of 99.00% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase & Co. downgraded shares of Amarin Co. plc from an “overweight” rating to a “neutral” rating in a research note to investors on Thursday. Separately, analysts at Leerink Swann cut their price target on shares of Amarin Co. plc to $6.00 in a research note to investors on Wednesday. Finally, analysts at Aegis downgraded shares of Amarin Co. plc from a “buy” rating to a “hold” rating in a research note to investors on Wednesday. They now have a $30.00 price target on the stock. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $9.04.
Shares of Amarin Co. plc (NASDAQ:AMRN) traded down 61.12% on Thursday, hitting $2.01. The stock had a trading volume of 105,694,200 shares. Amarin Co. plc has a 52-week low of $4.50 and a 52-week high of $12.96. The stock has a 50-day moving average of $6.47 and a 200-day moving average of $6.42. The company’s market cap is $347.0 million. Amarin Co. plc also was the recipient of some unusual options trading on Monday. Traders acquired 38,228 call options on the stock. This is an increase of 179% compared to the average volume of 13,680 call options.
Amarin Co. plc (NASDAQ:AMRN) last released its earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. On average, analysts predict that Amarin Co. plc will post $-1.38 earnings per share for the current fiscal year.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.